Subscribe
shutterstock_1652254300_taljat_david
Taljat David / Shutterstock.com
18 April 2023AmericasLiz Hockley

SCOTUS deals fresh blow to Novartis’ MS drug patent

Petition to review invalidation of Gilenya patent denied | Novartis challenged decision resulting from a change in judicial panel.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Why Novartis lost its treatment dispute with Teva
17 January 2023   The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.
Big Pharma
Novartis ‘abused’ discovery process for Zolgensma patent
23 May 2023   Two subsidiaries of the French pharma giant allege ‘wilful’ patent infringement by the Swiss-American pharma firm | Novartis ‘hid’ information in a previous lawsuit relating to spinal muscular atrophy drug used to treat young children.
Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
Why Novartis lost its treatment dispute with Teva
17 January 2023   The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.
Big Pharma
Novartis ‘abused’ discovery process for Zolgensma patent
23 May 2023   Two subsidiaries of the French pharma giant allege ‘wilful’ patent infringement by the Swiss-American pharma firm | Novartis ‘hid’ information in a previous lawsuit relating to spinal muscular atrophy drug used to treat young children.
Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

More on this story

Big Pharma
Why Novartis lost its treatment dispute with Teva
17 January 2023   The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.
Big Pharma
Novartis ‘abused’ discovery process for Zolgensma patent
23 May 2023   Two subsidiaries of the French pharma giant allege ‘wilful’ patent infringement by the Swiss-American pharma firm | Novartis ‘hid’ information in a previous lawsuit relating to spinal muscular atrophy drug used to treat young children.
Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent